Guggenheim Cuts Vigil Neuroscience (NASDAQ:VIGL) Price Target to $16.00

Vigil Neuroscience (NASDAQ:VIGL) had its price target cut by Guggenheim from $17.00 to $16.00 in a research report released on Wednesday, Benzinga reports. They currently have a buy rating on the stock.

Several other brokerages have also issued reports on VIGL. Wedbush reaffirmed an outperform rating and issued a $23.00 target price on shares of Vigil Neuroscience in a research note on Thursday, July 11th. HC Wainwright reaffirmed a buy rating and set a $17.00 target price on shares of Vigil Neuroscience in a report on Wednesday. Finally, JMP Securities reissued a market outperform rating and issued a $23.00 price target on shares of Vigil Neuroscience in a research note on Thursday, April 18th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Vigil Neuroscience currently has an average rating of Moderate Buy and a consensus target price of $16.60.

Vigil Neuroscience Stock Performance

Vigil Neuroscience stock opened at $3.49 on Wednesday. Vigil Neuroscience has a fifty-two week low of $2.47 and a fifty-two week high of $9.24. The stock has a market cap of $138.38 million, a P/E ratio of -1.65 and a beta of 2.00. The firm’s fifty day moving average price is $3.98 and its 200-day moving average price is $3.44.

Vigil Neuroscience (NASDAQ:VIGL) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.02. On average, analysts predict that Vigil Neuroscience will post -2.1 earnings per share for the current year.

Hedge Funds Weigh In On Vigil Neuroscience

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Vigil Neuroscience by 11.9% in the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock valued at $3,050,000 after acquiring an additional 95,276 shares in the last quarter. Ensign Peak Advisors Inc raised its holdings in Vigil Neuroscience by 72.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after purchasing an additional 166,442 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after purchasing an additional 11,536 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vigil Neuroscience during the 2nd quarter valued at about $87,000. Finally, Strs Ohio purchased a new position in shares of Vigil Neuroscience during the fourth quarter valued at about $27,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.